Page 105 - க்ஸ் உலகம் பல்கலைக்கழகம் தரவரிசை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AUSTIN, Texas /Massachusetts Newswire – National News/ Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King’s College London, a leading university providing world-class teaching and cutting-edge research, to support the Phase IIa GAMECHANgER-1 clinical trial. The trial aims to determine whether adoptive transfer of regulatory T cells (Tregs) into HLA sensitised patients can suppress memory T and B cell responses against specific HLA antigens in order to extend the longevity of donor organs.

United kingdomCity ofUnited statesAnthony dorlingResearch excellence frameworkEmergent technologies incKing college londonPure proteinPure transplant solutionsUniversity of oklahomaNational newsQs world university rankingsCentre for nephrologyMassachusetts newswireCollege londonTransplant inflammation